UPTRAVI® is the commercial brand name of Selexipag Tablets, an orally active selective prostacyclin IP-receptor agonist developed by Janssen. It selectively activates prostacyclin receptor on pulmonary vasculature to dilate pulmonary artery and inhibit vascular remodeling, delaying PAH progression.UPTRAVI Main IndicationsTreatment…
XPHOZAH® is the commercial brand name of Tenapanor Hydrochloride Tablets, an orally active sodium-hydrogen exchanger 3 (NHE3) inhibitor developed by Fosun Pharma. It blocks intestinal NHE3 to reduce sodium and water absorption from gut lumen, increasing intestinal fluid volume and…
Vocinti® is the commercial brand name of Vonoprazan Fumarate Tablets, an orally active potassium-competitive acid blocker (P-CAB) developed by Takeda. It competitively inhibits potassium binding site on gastric H+/K+-ATPase to suppress gastric acid secretion, achieving rapid and sustained acid inhibition…
Ultibro Breezhaler® is the commercial brand name of Indacaterol Maleate and Glycopyrronium Bromide Powder for Inhalation, a fixed‑dose combination inhaled bronchodilator developed by Novartis. Indacaterol maleate is a long‑acting β₂ agonist while glycopyrronium bromide is a long‑acting muscarinic antagonist; the…
Vyndamax® is the commercial brand name of Tafamidis Soft Capsules, an orally active transthyretin stabilizer developed by Pfizer. It binds to transthyretin tetramer to stabilize protein structure, prevents tetramer dissociation and subsequent amyloid fibril deposition in organs, thereby slowing the…
Vyndaqel® is the commercial brand name of Tafamidis Meglumine Soft Capsules, an orally active transthyretin stabilizer developed by Pfizer. It binds to transthyretin protein to stabilize its tetrameric structure, inhibit abnormal protein dissociation and amyloid deposition, thereby slowing disease progression…
Tecfidera® is the commercial brand name of Dimethyl Fumarate Enteric Capsules, an orally active immunomodulatory agent developed by Biogen. It exerts therapeutic effects via activating the Nrf2 antioxidant pathway and regulating inflammatory cytokine release, alleviating autoimmune inflammatory injury in the…
GILENYA® is the commercial brand name of Fingolimod Hydrochloride Capsules, an orally active sphingosine‑1‑phosphate (S1P) receptor modulator developed by Novartis. It binds to S1P receptors on lymphocytes to retain immune cells in lymph nodes and block their infiltration into the…
ZEPOSIA® is the commercial brand name of Ozanimod Hydrochloride Capsules, an orally active sphingosine-1-phosphate (S1P) receptor modulator developed by Bristol Myers Squibb. It selectively binds to S1P1 and S1P5 receptors on lymphocytes, traps lymphocytes within lymph nodes and limits their…
XTANDI® is the commercial brand name of Enzalutamide Soft Capsules, an orally active, second-generation non-steroidal androgen receptor inhibitor developed by Astellas Pharma. It exerts anti-tumor activity by competitively inhibiting androgen binding to the androgen receptor, blocking nuclear translocation of the…